0000000000975797

AUTHOR

Vincenzo Abbadessa

showing 46 related works from this author

The Impact of Venous Thromboembolism In Critically Ill Patients: A Meta-Analysis of Major Clinical outcomes

2010

Abstract Abstract 3327 Background: Critically ill patients are at high risk of developing venous thromboembolism (VTE) during their stay in the intensive care unit (ICU) because of premorbid medical and surgical conditions. The clinical consequences of Deep Vein Thrombosis (DVT) have the potential to be serious yet are frequently unrecognized in the Intensive Care Unit (ICU). In contrast to the extensive documentation on the short and long–term outcomes of patients with DVT evaluated in other clinical settings, little is known about the clinical course of this disease in the ICU setting. We hypothesized that both undetected and clinically evident VTE would affect the prognosis of critically…

Mechanical ventilationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentDeep veinImmunologyCell BiologyHematologyBiochemistryIntensive care unitConfidence intervallaw.inventionStudy heterogeneitymedicine.anatomical_structurelawRelative riskMeta-analysisEmergency medicinemedicineVenous thrombosis metaanalysisbusinessIntensive care medicineProspective cohort study
researchProduct

Erythromycin reverses the daunomycin resistance of MEL-DRTL cells

1990

PharmacologyChemistrymedicineErythromycinPharmacologymedicine.drugPharmacological Research
researchProduct

Novel Stilbene-Based Antileukemic Agents Active in P-Glycoprotein Expressing and Apoptosis-Resistant Acute Leukaemia Cell Lines.

2005

Abstract The stilbene scaffold is a basic element for a number of biologically active natural and synthetic compounds and in accordance with Evans’ definition it can be considered as a privileged structure. One of the most relevant and studied stilbenes is Resveratrol, a phytoalexin present in grapes, endowed with chemopreventive and chemotherapeutic properties and able to induce apoptosis in different cancer cell lines. Since reduced apoptosis has been implicated in the development and progression of malignant tumors and in the occurrence of chemoresistant phenotypes, resveratrol-induced apoptosis might therefore contribute to its antitumor activity. However, resveratrol is a not potent cy…

chemistry.chemical_classificationbiologyPhytoalexinImmunologyBiological activityCell BiologyHematologyCell cycleResveratrolBiochemistrychemistry.chemical_compoundchemistryBiochemistryCell cultureApoptosishemic and lymphatic diseasesbiology.proteinCytotoxic T cellP-glycoproteinBlood
researchProduct

Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients

2005

Outpatient treatment of deep vein thrombosis (DVT) has become a common practice in uncomplicated patients. Few data are still present in patients with comorbidity (such as cancer) or concomitant symptomatic pulmonary embolism. Cancer patients with DVT are often excluded from home treatment because they have a higher risk of both bleeding and recurrent DVT. We tested the feasibility and safety of the Home Treatment (HT) program for acute DVT a PE in cancer patients. Patients were treated as outpatients unless they required admission for other medical problems, were actively bleeding or had pain that requires parenteral narcotics. Outpatient treatment was with low molecular weight heparin (LM…

AdultMalemedicine.medical_specialtymedicine.drug_classHome NursingDeep veinLow molecular weight heparinSelf Administration.Patient Education as TopicRecurrenceNeoplasmsmedicineHumansAgedAged 80 and overVenous Thrombosisbusiness.industryWarfarinCancerHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisComorbidityHome Care ServicesPulmonary embolismSurgeryHospitalizationVenous thrombosismedicine.anatomical_structureOncologyFeasibility StudiesPatient ComplianceFemaleWarfarinbusinessPulmonary Embolismmedicine.drugFollow-Up Studies
researchProduct

Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell gro…

2005

New terphenyl derivatives have been synthesized and tested for their effect on cell survival in serum-free cultures. These compounds protected HL60 cells from death and supported their growth with an activity higher than that of the natural 14-hydroxy-retro-retinol. Terphenyls 26 and 28 also possess antiapoptotic activity on neuronal cells, proving them as possible candidates for the treatment of neurodegenerative and ischemic diseases.

Programmed cell deathNecrosisreceptor-alphamedicine.drug_classmechanismApoptosisHL-60 Cellsnecrosischemistry.chemical_compoundRetinoidsdeathTerphenylDrug DiscoverymedicineHumansRetinoidNeuronsCell growthbiphenyl-4-carboxylic acidarotinoidIn vitroCell biologyCultured cortical-neuronchemistryBiochemistryCell cultureApoptosisretinobenzoic acidMolecular MedicineIndicators and Reagentsmultidrugmedicine.symptomCell Division(14R)-14-hydroxy-414-retro-retinolJournal of medicinal chemistry
researchProduct

Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma

2006

Abstract: Objectives: Solid second primary cancers (SPC) have become an issue of extensive research. The purpose of the present study was to estimate the standardised incidence ratio (SIR) and the absolute excess risk (AER) of SPC in patients with splenic marginal zone lymphoma (SMZL). Methods: We investigated the incidence of additional cancers in 129 patients consecutively diagnosed with SMZL in three Italian haematological centres, asking the cooperating doctors for additional information on initial and subsequent therapies and on the onset and type of second cancers. Results: Twelve SPC were recorded (9.3%); the 3- and 5-yr cumulative incidence rates were 5.5% and 18.3% respectively, wi…

Oncologymedicine.medical_specialtyLymphomaPopulationsplenic marginal zone lymphomaBreast cancerInternal medicinemedicinecancerHumansCumulative incidenceSplenic marginal zone lymphomaLung cancereducationAgededucation.field_of_studysplenic marginal zone lymphoma cancerbusiness.industryIncidenceSplenic Neoplasmsadditional cancerCancerNeoplasms Second PrimarySplenic lymphoma with villous lymphocytesHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomabusinessEuropean Journal of Haematology
researchProduct

Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.

2010

Several publications have focused on the cardiotoxicity of specific classes of haematological therapeutic agents such as antracyclines and cyclofosfamide. Cardiotoxicity of cancer chemotherapeutics is a problem for patients of all ages, but it increases with age. Toxicity can also be developed months after the last chemotherapy dose, and late reactions can be seen years later when they present new-onset cardiomyopathy. No data are available about the cardiotoxicity of non-chemotherapy agents currently used as preferred therapy for haematological malignancy in elderly. In this review we have provided a summary of the cardiovascular toxic effects produced by different drugs and therapeutic ag…

Drugmedicine.medical_specialtyHeart diseaseHeart Diseasesmedicine.medical_treatmentmedia_common.quotation_subjectCardiomyopathyAntineoplastic AgentsPharmacologyCardiotoxinsDrug Delivery SystemsDrug DiscoverymedicineAnimalsHumansIntensive care medicinedrug cardiotoxicity haematological malignanciesmedia_commonAgedPharmacologyCardiotoxicityChemotherapybusiness.industryAge FactorsCancerImatinibmedicine.diseaseHematologic NeoplasmsRituximabbusinessmedicine.drugCurrent pharmaceutical design
researchProduct

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

2005

: Background: Splenic marginal zone lymphoma (SMZL) is an infrequent B-cell neoplasm that pursues an indolent course. Signs and symptoms, mostly related to hypersplenism, are successfully managed by splenectomy. However, the therapy of patients who are not fit for a surgical procedure or who relapse after splenectomy, is still an unsettled issue. Patients and methods: We report a phase-II study on 16 patients with SMZL, three therapy naive and 13 pretreated, all showing systemic symptoms or progressive worsening of peripheral cytopenia, who were treated with pentostatin at a dose of 4 mg/m2 every other week for 6–10 wk. In relapsed patients, the median interval between diagnosis and treatme…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSplenectomyPurine analogueDrug Administration SchedulemedicinePentostatinHumansProgression-free survivalSplenic marginal zone lymphomaLymphocytesAgedCytopeniaDeoxycoformycinbusiness.industrySplenic NeoplasmsRemission InductionNeoplasms Second PrimaryHematologyGeneral MedicineLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseSMZLSurvival AnalysisSurgerysplenic marginal zonelymphomaDeoxycoformycinFemaleSplenic LymphomabusinessPentostatinvillous lymphocytesmedicine.drugEuropean journal of haematology
researchProduct

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

2004

Abstract Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for haematological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 on lymphoid cells, produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed a full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab. Lam…

HepatitisHepatitis B virusHBsAgmedicine.diagnostic_testCD52business.industryImmunologyvirus diseasesLamivudineCell BiologyHematologyHepatitis Bmedicine.diseasemedicine.disease_causeBiochemistrydigestive system diseasesLiver biopsyImmunologymedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells

1996

4-Demethoxydaunorubicin (idarubicin, IDA) is an anthracycline that has shown good cytotoxic activity in vitro against tumor cell lines displaying the multidrug-resistant (MDR) phenotype. IDA is converted in the liver into idarubicinol (2HIDA) and, in this form, seems to exert its antitumoral activity in vivo. Recent studies have shown that 2HIDA has tumoricidal activity similar to that of the parent drug when tested in vitro in sensitive neoplastic cells. In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562. IDA and 2HI…

Cancer ResearchAnthracyclineAntineoplastic AgentsPharmacologyBiologyToxicologyIn vivohemic and lymphatic diseasesCyclosporin aAntineoplastic Combined Chemotherapy ProtocolsTumor Cells CulturedmedicineCytotoxic T cellIdarubicinPharmacology (medical)PharmacologyAntibiotics AntineoplasticDaunorubicinnutritional and metabolic diseasesFlow CytometryDrug Resistance MultipleIn vitroMultiple drug resistanceOncologyCell cultureCyclosporineIdarubicinImmunosuppressive Agentsmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Monocyte and lymphocyte apoptosis resistance in acute and chronic brucellosis and its possible implications in clinical management.

2003

This study evaluated the level of susceptibility of monocytes and lymphocytes to spontaneously induced and CH11-induced apoptosis in 16 patients with Brucella infection. The expression of some immunological and apoptotic markers was evaluated. Before therapy, monocytes showed a high level of resistance to spontaneously induced or CH11-induced apoptosis in all patients. In patients with acute infection, this resistance persisted for 10-20 days after treatment was initiated, then decreased; in chronically infected patients, it persisted after 45 days of treatment. Lymphocytes were also more resistant to CH 11-induced apoptosis. The level of activated CD8++ T lymphocytes was high in patients w…

Microbiology (medical)AdultAdolescentLymphocyteApoptosisBrucellaCD8-Positive T-LymphocytesMonocyteBrucellosisMonocytesBrucellosimedicineHumansLymphocytesfas ReceptorChildbiologybusiness.industryMonocyteAntibodies MonoclonalBrucellosisCD8-Positive T-LymphocyteT lymphocytebiology.organism_classificationmedicine.diseaseBrucellaInfectious Diseasesmedicine.anatomical_structureApoptosisChild PreschoolImmunologyAcute DiseaseChronic Diseasebiology.proteinLymphocyteAntibodybusinessCD8Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Cancer Patients Requiring Interruption of Long-Term Anticoagulant Therapy: The Use of Fixed Sub-Therapeutic Doses of Low-Molecular Weight Heparin

2011

Abstract Abstract 1244 Introduction. We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in cancer patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures (defined as major and non major surgery) or chemotherapy inducing platelets depletion. Methodology. Cancer patients were defined to be at high (atrial fibrillation [AF] with previous stroke, prosthetic mitralic valves and venous thromboembolism [VTE] lasting < 3months) or low risk of thrombosis (AF without previous stroke, VTE lasted > 3 months, and prosthetic aortic valves). They discontinued VKA 5 + 1days before surgery or chemotherapy; in those at low-risk f…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentImmunologyLow molecular weight heparinAtrial fibrillationCell BiologyHematologyHeparinmedicine.diseaseBiochemistryChemotherapy regimenThrombosisSurgeryAnesthesiaNadroparinMedicinebusinessStrokemedicine.drugBlood
researchProduct

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

2009

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5…

Malemedicine.medical_specialtyPathologyLeukocytosismyeloproliferative neoplasm thrombosis jak2GastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeSettore MED/15 - Malattie Del SangueLeukocyte CountPolycythemia verahemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaLeukocytosisRisk factorProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedbusiness.industryEssential thrombocythemiaHazard ratioThrombosisHematologyGeneral MedicineJanus Kinase 2Middle Agedmedicine.diseaseThrombosisMultivariate AnalysisFemalemedicine.symptombusinessThrombocythemia Essential
researchProduct

Identification of a Terphenyl Derivative that Blocks the Cell Cycle in the G0−G1 Phase and Induces Differentiation in Leukemia Cells

2006

To further explore the SAR of resveratrol-related trans-stilbene derivatives, here we describe the synthesis of (a) a series of 3,5-dimethoxy analogues in which a variety of substituents were introduced at positions 2', 3', 4', and 5' of the stilbene scaffold and (b) a second group of derivatives (2-phenylnaphthalenes and terphenyls) that incorporate a phenyl ring as a bioisosteric replacement of the stilbene alkenyl bridge. We thoroughly characterized all of the new compounds with respect to their apoptosis-inducing activity and their effects on the cell cycle. One of the new derivatives, 13g, behaved differently from the others, as it was able to block the cell cycle in the G(0)-G(1) phas…

StereochemistryCellular differentiationFusion Proteins bcr-ablAntineoplastic AgentsApoptosis.ResveratrolResting Phase Cell CycleChemical synthesisStructure-Activity Relationshipchemistry.chemical_compoundLeukemia Promyelocytic AcuteCell Line TumorTerphenyl CompoundsTerphenylStilbenesDrug DiscoveryHumansStructure–activity relationshipATP Binding Cassette Transporter Subfamily B Member 1G1 PhaseCell DifferentiationCell cycleIn vitrochemistryDrug Resistance NeoplasmResveratrolCell cultureMolecular MedicineDrug Screening Assays AntitumorJournal of Medicinal Chemistry
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: F…

2009

Abstract Abstract 4276 Introduction Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. As most of the data concerning the efficacy of the drug derive either from a single sponsored trial or from single institution reports, we decided to accrue all CML pts diagnosed in the Italian region of Sicily to the observational SCREEN (Siciliy CML Regional Enterprise) study, to evaluate the hematological, cytogenetic and molecular responses of this unselected population to IM. Patients and Methods Although the study is still ongoing, 173 consecutive CML pts have been enrolled between Januar…

medicine.medical_specialtyeducation.field_of_studybusiness.industryImmunologyPopulationMyeloid leukemiaCell BiologyHematologymedicine.diseaseInterim analysisBiochemistrySurgeryLeukemiaImatinib mesylateMulticenter studyInternal medicinemedicineProgression-free survivaleducationbusinessComplete Hematologic Response
researchProduct

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

2007

Abstract The majority of patients (pts) with acute myeloid leukemia (AML) are diagnosed in their 6th and 7th decade of life. AML in elderly pts is associated with poor response to conventional chemotherapy and limited long-term survival, reflecting a higher incidence multidrug resistance mechanisms, a low bone marrow reserve which may prevent/delay the recovery of hematopoiesis after treatment, and the occurrence of co-morbidities. Gemtuzumab ozogamicin (GO) is an immunoconjugate with a humanized anti-CD33 that after internalization, releases a cytotoxic drug, calicheamicin; ≥80% of AML pts have myeloid blast cells that express the CD33 surface antigen. GO as a single agent has low antileuk…

Oncologymedicine.medical_specialtyGemtuzumab ozogamicinbusiness.industryImmunologyCombination chemotherapyCell BiologyHematologyHematology myeloid leukemia (AML)BiochemistrySurgeryFludarabineMaintenance therapyInternal medicineCyclosporin amedicineFLAG (chemotherapy)IdarubicinbusinessEtoposidemedicine.drugBlood
researchProduct

Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antir…

2003

Aims: Highly active antiretroviral therapy (HAART) can induce an increase in lactic acid concentrations that seems to be caused by mitochondrial dysfunction induced by the interaction of nucleoside reverse transcriptase inhibitors (NRTIs) with DNA polymerase γ in the mitochondria. Mitochondrial alterations have been described in liver and muscle cells of NRTI treated human immunodeficiency virus (HIV) infected patients. Because lymphocytes are the main target for HIV and because mitochondria are involved in apoptosis, we studied mitochondrial morphology and apoptosis in the lymphocytes of an HIV infected patient with severe lactic acidosis after treatment with stavudine, didanosine, and ind…

Adultmedicine.medical_specialtyAnti-HIV AgentsLymphocyteApoptosisHIV InfectionsCase ReportsMitochondrionBiologyPathology and Forensic Medicinechemistry.chemical_compoundimmune system diseasesIndinavirAntiretroviral Therapy Highly ActiveInternal medicinemedicineHumansLymphocytesDidanosineAcridine orangeStavudinevirus diseasesGeneral Medicinemedicine.diseaseMitochondriaEndocrinologymedicine.anatomical_structurechemistryApoptosisLactic acidosisImmunologyAcidosis LacticFemalemedicine.drugJournal of Clinical Pathology
researchProduct

Polycythemia Vera as a Predisposing Factor for Aortic Stenosis: Prevalence and Correlation with Blood Cells Count and Mutational Status

2008

Abstract The association between Polycythemia Vera (PV) and thrombosis is multi-factorial involving the complex interaction between activated leukocytes, platelets and endothelium. Recent reports have postulated that PV patients may over express adhesive molecules on red cell surface, likely by JAK2 mutation (Wautier M et al. Blood.2007;110(3):894–901). This process activates endothelium with production of vascular growth factors and other mechanisms leading to atherosclerosis. Aortic Stenosis (AS) is the commonest valvular heart disease in western countries; its pathogenesis is mainly related to a degenerative process sharing many characteristics with atherosclerosis. At the present is not…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyvalvular heart diseaseCell BiologyHematologyHematocritmedicine.diseaseBiochemistryThrombosisGastroenterologySurgeryStenosisPolycythemia veraDiabetes mellitusRelative riskInternal medicineHeart failuremedicinebusinessBlood
researchProduct

Primary gastrointestinal involvement in non-Hodgkin's lymphomas.

1987

This paper reviews primary gastrointestinal non-Hodgkin's lymphoma (GI-NHL). Every aspect of the topic is discussed though special attention is paid to histopathology and instrumental diagnosis as essential factors to stage the lymphoma and to determine an adequate therapy. Data from the most important works on the subject together with the results of our recent study of 40 primary GI-NHL are reported. Diverse findings by various authors are intentionally compared in a manner to present the work to the reader in the most critical way while trying to give an objective explanation of the different results on the basis of our own experience.

Adultmedicine.medical_specialtyPathologyAdolescentMEDLINEimmune system diseaseshemic and lymphatic diseasesmedicineCombined Modality TherapyHumansChildAgedGastrointestinal NeoplasmsNeoplasm StagingUltrasonographyAged 80 and overHodgkin sbusiness.industryLymphoma Non-HodgkinHematologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyLymphomaRadiographyHistopathologyNeoplasm stagingRadiologyUltrasonographybusinessActa haematologica
researchProduct

Pterostilbene and 3′-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells

2005

Pterostilbene and 3,5-hydroxypterostilbene are the natural 3,5-dimethoxy analogs of trans-resveratrol and piceatannol, two compounds which can induce apoptosis in tumor cells. In previous studies we demonstrated the importance of a 3,5-dimethoxy motif in conferring pro-apoptotic activity to stilbene based compounds so we now wanted to evaluate the ability of pterostilbene and 3,5-hydroxypterostilbene in inducing apoptosis in sensitive and resistant leukemia cells. When tested in sensitive cell lines, HL60 and HUT78, 3'-hydroxypterostilbene was 50-97 times more potent than trans-resveratrol in inducing apoptosis, while pterostilbene appeared barely active. However, both compounds, but not tr…

PiceatannolLeukemiaPterostilbeneABLHL60ApoptosisCell BiologyGenes ablBiologyBiochemistrystilbenes leukemia BCR-ABL multidrug resistance apoptosischemistry.chemical_compoundImatinib mesylatePhenolsBiochemistrychemistryApoptosisCell cultureCell Line TumorStilbenesCancer researchHumansfas ReceptorGenes MDRStem cellThe International Journal of Biochemistry & Cell Biology
researchProduct

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

2015

Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes. The resulting BCR-ABL1 oncogene leads to increased proliferation and survival of leukemic cells. Successful treatment of CML has been accompanied by steady improvements in our capacity to accurately and sensitively monitor therapy response. Currently, measurement of BCR-ABL1 mRNA transcript levels by real-time quantitative PCR (RQ-PCR) defines critical response endpoints. An antibody-based technique for BCR-ABL1 protein recognition could be an attractive alternative to RQ-PCR. To date, there have been no studies evaluating whether flow-cytometr…

Genetics and Molecular Biology (all)medicine.medical_specialtyScienceFusion Proteins bcr-ablBiologyBiochemistryPolymerase Chain ReactionInternal medicinehemic and lymphatic diseasesmedicineHumansAgricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)In Situ Hybridization FluorescenceImmunoassayMultidisciplinaryABLHematologymedicine.diagnostic_testMedicine (all)QRbreakpoint cluster regionMyeloid leukemiaLeukemia Myelomonocytic Chronicmedicine.diseaseFlow CytometryMolecular biologyFusion proteinLeukemiaReal-time polymerase chain reactionAgricultural and Biological Sciences (all)ImmunoassayMedicineResearch ArticlePLoS ONE
researchProduct

Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines

2005

Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was replaced either by a five-membered heterocyclic (isoxazoline or isoxazole) or by a six-membered ring (pyridine or benzene). The new compounds have been evaluated for their effects on tubulin assembly and for cytotoxic and apoptotic activities. Five compounds (18b, 20a, 21a, 34b, and 35b) demonstrated an attractive profile of cytotoxicity (IC501 microM) and apoptosis-inducing activity but poor antitubulin activity. The isoxazoline derivatives 18b, 20a, and 21a, demonstrated potent apoptotic activity different from that of natural CA-4. Their ability to block most cells in the G2 phase suggests…

Models MolecularA-4 ANALOGSDouble bondHL60StereochemistryPyridinesTUBULINApoptosisANTINEOPLASTIC AGENTSchemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryStilbenesBenzene DerivativesHumansIsoxazoleBIOLOGICAL EVALUATIONCytotoxicitychemistry.chemical_classificationCombretastatinbiologyCOLCHICINEDEATHIsoxazolesDrug Resistance MultipleTubulinANTIMITOTIC ANTITUMOR AGENTSMULTIDRUGchemistryApoptosisCell cultureDrug Resistance NeoplasmDISCOVERYbiology.proteinMolecular MedicineDrug Screening Assays AntitumorSOLID TUMOR-THERAPY
researchProduct

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

2006

Abstract Cytomegalovirus (CMV) is an important cause of morbidity and mortality in patients who have undergone severe immunosuppressive therapy. Ganciclovir continues to be the first choice for pre-emptive therapy, but it needs multiple intravenous daily administration for three weeks and may cause myelosuppression. Cidofovir is a non myelotoxic nucleotide analogue effective against CMV; its favourable pharmacokinetic profile allows a once-a-week dosing. We reviewed a database on 110 consecutive Autologous Stem Cell Transplant (ASCT) and that of 15 Chronic Lymphocytic Leukemia (CLL) patients treated with alemtuzumab. All patients were virologically monitored by quantification of pp65 antige…

Ganciclovirmedicine.medical_specialtyNauseaChronic lymphocytic leukemiaImmunologyCongenital cytomegalovirus infectionBiochemistryGastroenterologySettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicinemedicineProteinuriabusiness.industryvirus diseasesCell BiologyHematologymedicine.diseaseSurgerychemistryVomitingCytomegalovirus pre-emptive treatment cidofovirAlemtuzumabmedicine.symptombusinessmedicine.drugCidofovirBlood
researchProduct

Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.

2009

Aims: Essential thrombocythaemia (ET) and primary myelofibrosis (PMF) share some clinical and pathological features, but show different biological behaviour and prognosis. The latest contributions to understanding the nature of these disorders have focused on bone marrow microenvironment remodelling and proliferative stress, recognising megakaryocytes (MKCs) as “key-cells”. The aim of this study was to investigate the apoptotic profile of ET and PMF MKCs in order to further characterise the biology of these disorders. Methods: Bone marrow biopsy samples from 30 patients with ET, and 30 patients with PMF, were immunophenotypically studied for the expression of pro-apoptotic (Fas, Fas-L, Bax,…

AdultMalePathologymedicine.medical_specialtyBiopsyIDIOPATHIC MYELOFIBROSISApoptosisPOLYCYTHEMIA-VERASettore MED/08 - Anatomia PatologicaBiologyPathology and Forensic MedicineImmunophenotypingImmunophenotypingMegakaryocyteBone MarrowmedicineIn Situ Nick-End LabelingHumansTelomerase reverse transcriptaseMyelofibrosisMOLECULAR PERSPECTIVEAgedAged 80 and overTUNEL assayEssential thrombocythemiaC-MPLMUTATION STATUSGeneral MedicineMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureCHRONIC MYELOPROLIFERATIVE DISORDERSCELL-DEATHApoptosisPrimary MyelofibrosisRISK-FACTORSCancer researchBONE-MARROW ANGIOGENESISMYELOID METAPLASIAFemaleBone marrowMegakaryocytesThrombocythemia EssentialJournal of clinical pathology
researchProduct

Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial.

2006

Abstract Background. Most of the patients with advanced stage Hodgkin lymphoma can be cured with a standard course of six cycle of ABVD chemotherapy plus involved field (IF)radiotherapy. Patients with less advanced stage or with a more responsive disease could possibly achieve a cure with a shorter course of chemotherapy. In 1992, in the pre-PET era, the GISL addressed the issue of the proper number of chemotherapy cycles planning a response-oriented, ABVD-based study for intermediate-stage Hodgkin’s lymphoma patients. Patients and Methods. From January 1992 to December 2002, 218 patients younger than 70 were enrolled. Eligible patients had histologically confirmed and clinically staged Hod…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentImmunologyPhysical examinationCell BiologyHematologymedicine.diseaseBiochemistrySurgeryLymphomaRadiation therapyNodular sclerosisABVDErythrocyte sedimentation ratemedicineStage (cooking)businessProgressive diseasemedicine.drug
researchProduct

PREDICTORS OF RESIDUAL VEIN THROMBOSIS AFTER CANCER-RELATED DEEP VEIN THROMBOSIS OF THE LOWER LIMBS

2012

Thrombosicancer
researchProduct

Effects of Propolis in cancer cells

2006

researchProduct

Presenting features and outcome of Splenic Marginal Zone Lymphoma with or without villous lymphocytes. A retrospective analysis in a Series of 145 Pa…

2004

researchProduct

Screening sierologico per Leishmania infantum su donatori di sangue e HIV+ asintomatici residenti in area endemica [Serological screening for Leishma…

2008

Visceral leishmaniasis (VL) is endemic in Sicily (48 new cases in 2004, of which nine were in Agrigento). In southern Europe between 25-70 per cent of adult VL cases are related to HIV infection. The HIV cases have a high risk (1.5-9%) of developing VL either as a new infection or as the revival of a latent infection. We therefore carried out serologic screening to detect antibodies against L. infantum by IFAT in 1449 blood donors in Agrigento and the surrounding area (May-December 2005) and in 120 HIV+ in western Sicily, all of whom were asymptomatic and had no history of VL. L. DNA was assessed by nested PCR in blood samples of some seropositive donors. Of the 1449 blood donors, 11 (0.75%…

Blood donors Coinfection HIV LeishmaniasisSettore MED/15 - Malattie Del Sangue
researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER S…

2012

multiple myeoloma lymphocite count prognostic factorsSettore MED/15 - Malattie Del Sangue
researchProduct

Successful treatment of acquired haemophilia with FEIBA and Retuximab

2005

researchProduct

CANCER AS A PREDICTOR FOR INCREASED PERIPROCEDURAL BLEEDING DURING SURGERY OR PLATELET-INDUCED CHEMOTHERAPY IN CHRONICALLY ANTICOAGULATED PATIENTS

2012

Anticoagulation bleedingSettore MED/15 - Malattie Del Sangue
researchProduct

“Weekly regimen of cisplatin, epirubicin, 5-Fluorouracil and folinic acid with G-CSF is active in advanced gastroesophageal (GE) and gastric (G) canc…

2004

researchProduct

INFEZIONE DA HIV E IMMIGRATI NEGLI ULTIMI CINQUE ANNI DI ATTIVITA' DEL NOSTRO CENTRO

2006

researchProduct

ENDOGENOUS THROMBIN POTENTIAL IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOSIS

2007

researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

2012

multiple myelomalymphocyte count
researchProduct

Screening sierologico per l'infantum in soggetti HIV+ in area endemica Sicilia occidentale

2006

researchProduct

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.

2005

AbstractIn contrast with extensive documentation in patients treated with unfractionated heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a prospective cohort study, the platelet count was monitored in 1754 consecutive patients referred to 17 medical centers and treated with LMWH for prophylaxis or treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case of a platelet drop of at least 50%, the absence of obvious explanations for thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT developed in 14 patients (0.80%; 95% CI, 0.43%-1…

AdultMalemedicine.medical_specialtymedicine.drug_classImmunologyLow molecular weight heparinheparinPlatelet Factor 4BiochemistryCohort StudiesRisk FactorsHeparin-induced thrombocytopeniaInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)IncidenceCell BiologyHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaSurgeryClinical trialTreatment OutcomeFemaleComplicationbusinessCohort studymedicine.drugBlood
researchProduct

Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients

2006

researchProduct

ABSOLUTE LYMPHOCYTE COUNT AS PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

2011

multiple myelomaSettore MED/15 - Malattie Del Sangue
researchProduct

Apoptosis in infectious diseases

2004

researchProduct

Pre-empitive treatment with ciclofovir for cytomegalovirus antigenemia in autologous bone marrow recipient and CLL patients on therapy with alentuzum…

2006

researchProduct

Presenting features and prognostic factors in Splenic Marginal Zone Lymphoma. A study on 145 patients.

2005

researchProduct

CD200 ANTIGEN IN B-CELL DERIVED NEOPLASMS: EXPRESSION AND CLINICAL IMPACT IN 77 CONSECUTIVE PATIENTS OF A SINGLE ISTITUTION

2012

cytofluorimetrylymphoprolyferative disease
researchProduct

PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE

2012

PJP infection Haematological neoplasmsSettore MED/15 - Malattie Del Sangue
researchProduct